Active Biotech’s partner Teva initiates a laquinimod clinical trial in Huntington’s disease

2160

Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that its partner Teva Pharmaceutical Industries Ltd. will initiate a phase II clinical trial to evaluate the efficacy and safety of oral laquinimod for the treatment of Huntington’s disease. For further details please see www.clinicaltrials.gov .

About laquinimod
Laquinimod is a once-daily oral, investigational, CNS-active immunomodulator with a novel mechanism of action being developed primarily for the treatment of relapsing-remitting MS (RRMS) and progressive forms of MS. In extensive non-clinical and clinical studies, laquinimod has demonstrated both anti-inflammatory and neuroprotective properties and effects that have been shown to provide clinically meaningful results.

About Active Biotech 
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. In pivotal phase is laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis. Also tasquinimod for the treatment of prostate cancer, with a unique mode of action, is in pivotal phase. In addition, laquinimod has concluded Phase II development for Crohn’s and Lupus. The company has two additional projects in clinical development, ANYARA primarily for the treatment of renal cell cancer and the orally administered compound paquinimod (57-57) for systemic sclerosis. Please visit www.activebiotech.com for more information.

READ MORE

Source: Active Biotech

Print Friendly, PDF & Email